{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:01:45Z","timestamp":1785348105428,"version":"3.55.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study explored the potential association between paclitaxel (PTX) and macular oedema (ME), a rare adverse event, through pharmacovigilance analysis using a large-scale spontaneous reporting database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality analysis of ME associated with PTX formulations, including nanoparticle albumin-bound PTX (nab\u2011PTX) was conducted using the Japanese Adverse Drug Event Report database on data collected during April 2004\u2013June 2025. Multivariable logistic regression analysis was used to estimate adjusted reporting odds ratios (RORs) for ME. A positive signal was defined as a lower 95% confidence interval (CI) for the ROR exceeding 1.0 with at least three ME cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 585,738 reports, 123 involved ME. A significant signal was observed for overall PTX (adjusted ROR: 19.5; 95% CI: 13.5\u201328.3). By formulation, significant signals were identified for conventional PTX (adjusted ROR: 9.4; 95% CI: 5.5\u201316.1) and nab\u2011PTX (adjusted ROR: 47.0; 95% CI: 30.4\u201372.8). Multivariable logistic regression indicated significant signals for diabetes mellitus (adjusted ROR: 1.8; 95% CI: 1.2\u20132.9) and co-administration of prostaglandin analogue eye drops (adjusted ROR: 19.9; 95% CI: 8.6\u201345.7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PTX formulations were associated with an increased reporting signal of ME. Notably, patients with diabetes mellitus and those using prostaglandin analogue eye drops may require closer ophthalmologic monitoring during PTX therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354959","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:40:53Z","timestamp":1785346853000},"page":"e0354959","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2011world analysis of Macular Oedema associated with Paclitaxel Formulations using the Japanese Adverse Drug Event Report database"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7712-5714","authenticated-orcid":true,"given":"Koki","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayu","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinka","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-1237","authenticated-orcid":true,"given":"Nobuhito","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"pone.0354959.ref001","volume-title":"Macular edema","author":"National Eye Institute","year":"2025"},{"issue":"5","key":"pone.0354959.ref002","article-title":"Occam Versus Hickam: Irreversible Vision Loss From Paclitaxel-Induced Cystoid Macular Edema","volume":"9","author":"KC Allan","year":"2025","journal-title":"J Vitreoretin Dis"},{"issue":"5","key":"pone.0354959.ref003","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.disamonth.2021.101138","article-title":"Diabetic macular edema","volume":"67","author":"M Ixcamey","year":"2021","journal-title":"Dis Mon"},{"issue":"22","key":"pone.0354959.ref004","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.3390\/s25226879","article-title":"Explainable Artificial Intelligence Framework for Predicting Treatment Outcomes in Age-Related Macular Degeneration","volume":"25","author":"MH Wang","year":"2025","journal-title":"Sensors (Basel)"},{"issue":"1","key":"pone.0354959.ref005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/diagnostics16010046","article-title":"Early Detection of Cystoid Macular Edema in Retinitis Pigmentosa Using Longitudinal Deep Learning Analysis of OCT Scans","volume":"16","author":"F Hosseini","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"pone.0354959.ref006","doi-asserted-by":"crossref","first-page":"1694311","DOI":"10.3389\/fphar.2025.1694311","article-title":"Effectiveness and safety of tocilizumab in refractory noninfectious uveitis: a systematic review and meta-analysis","volume":"16","author":"H Kang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0354959.ref007","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/jcm15020622","article-title":"Dim Flicker: An Endogenous Visual Percept and Its Disease Associations","volume":"15","author":"A Amini","year":"2026","journal-title":"J Clin Med"},{"key":"pone.0354959.ref008","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/OPTH.S31902","article-title":"Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy","volume":"6","author":"R Singh","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"pone.0354959.ref009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ogla.2024.07.010","article-title":"Incidence of Acute Cystoid Macular Edema after Starting a Prostaglandin Analog Compared with Other Classes of Glaucoma Medications","volume":"8","author":"SOURCE Consortium","year":"2025","journal-title":"Ophthalmol Glaucoma"},{"issue":"1","key":"pone.0354959.ref010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-025-00856-9","article-title":"Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study","volume":"26","author":"X Li","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0354959.ref011","first-page":"24741264251412082","article-title":"Inherited Retinal Disease as a Predisposing Factor for Paclitaxel Maculopathy","author":"RS Meshkin","year":"2026","journal-title":"J Vitreoretin Dis"},{"issue":"10","key":"pone.0354959.ref012","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.annonc.2025.06.004","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline","volume":"36","author":"LEL Hendriks","year":"2025","journal-title":"Ann Oncol"},{"key":"pone.0354959.ref013","unstructured":"European Society for Medical Oncology. Management of epithelial ovarian cancer. https:\/\/www.guidelinecentral.com\/guideline\/5034801\/#section-5034805 Accessed 2026 January 28."},{"issue":"4","key":"pone.0354959.ref014","doi-asserted-by":"crossref","first-page":"104528","DOI":"10.1016\/j.esmoop.2025.104528","article-title":"ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer","volume":"10","author":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org","year":"2025","journal-title":"ESMO Open"},{"issue":"11","key":"pone.0354959.ref015","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1248\/bpb.b18-00444","article-title":"Risk Factors for Eye Disorders Caused by Paclitaxel: A Retrospective Study","volume":"41","author":"Y Noguchi","year":"2018","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"pone.0354959.ref016","first-page":"3","article-title":"Unraveling the Mystery of Taxol-Induced Cystoid Macular Oedema: Case Report and Literature Review","volume":"69","author":"R Babovic","year":"2025","journal-title":"Rom J Ophthalmol"},{"issue":"1","key":"pone.0354959.ref017","doi-asserted-by":"crossref","first-page":"19530","DOI":"10.1038\/s41598-024-69775-9","article-title":"Incidence and prognosis of taxane-induced macular edema: a retrospective study from the Japan Clinical REtina Study Group (J-CREST)","volume":"14","author":"H Tsujinaka","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0354959.ref018","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00228-025-03931-6","article-title":"Itraconazole-associated adverse events in fungal infections: a study of a large real-world sample based on the FAERS database (2019-2024)","volume":"82","author":"T Xia","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0354959.ref019","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany","volume":"18","author":"F Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"pone.0354959.ref020","unstructured":"College ter Beoordeling van Geneesmiddelen (CBG-MEB). Bugvi 5 mg\/ml poeder voor dispersie voor infusie: Summary of Product Characteristics (SmPC). https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h129035_smpc_en.pdf Accessed 2026 February 17."},{"issue":"3","key":"pone.0354959.ref021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ogla.2025.12.010","article-title":"A Large-Scale Cohort Analysis of Topical Prostaglandin Analog Use and Pseudophakic Cystoid Macular Edema Following Cataract Surgery","volume":"9","author":"J Muayad","year":"2026","journal-title":"Ophthalmol Glaucoma"},{"issue":"1","key":"pone.0354959.ref022","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10792-024-03362-9","article-title":"Carbonic anhydrase inhibitor alleviates retinal barrier toxicity in paclitaxel-induced retinopathy and macular edema by inhibiting CAXIV","volume":"44","author":"Y-T Ye","year":"2024","journal-title":"Int Ophthalmol"},{"key":"pone.0354959.ref023","unstructured":"Genentech Inc. LUCENTIS [package insert]. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d&type=display 2025. Accessed 2025 August 6."},{"issue":"7","key":"pone.0354959.ref024","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/ijms22073427","article-title":"Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema","volume":"22","author":"H Noma","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0354959.ref025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","article-title":"Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis","volume":"139","author":"X Guo","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"pone.0354959.ref026","unstructured":"Northstar Rx LLC. Paclitaxel injection, solution. https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=e47c2c34-0466-4219-be6f-97e4231ed55f 2021. Accessed 2025 August 6."},{"key":"pone.0354959.ref027","unstructured":"Pharmaceuticals, Inc. T. Paclitaxel injection, powder, lyophilized, for suspension. https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=15dd51ed-29e8-468b-b6d1-21b1f84d6f2e 2023. Accessed 2025 August 6."},{"issue":"26","key":"pone.0354959.ref028","first-page":"00123","article-title":"Maculopathy in Paclitaxel Users: Nationwide Drug Use, Incidence, and Risk Factors","author":"H Sunjin","year":"2026","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"pone.0354959.ref029","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3341\/kjo.2012.26.5.388","article-title":"A case of cystoid macular edema associated with Paclitaxel chemotherapy","volume":"26","author":"DS Ham","year":"2012","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"pone.0354959.ref030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000477897","article-title":"Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review","volume":"10","author":"T Yokoe","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"18","key":"pone.0354959.ref031","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"DD Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0354959.ref032","doi-asserted-by":"crossref","first-page":"294","DOI":"10.20344\/amp.13421","article-title":"Macular Cystoid Edema Induced by Nab-Paclitaxel","volume":"35","author":"S Alves Pereira","year":"2022","journal-title":"Acta Med Port"},{"issue":"7","key":"pone.0354959.ref033","first-page":"599","article-title":"A Case of Cystoid Macular Edema Secondary to Albumin-Bound Paclitaxel Therapy","volume":"44","author":"T Ito","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"pone.0354959.ref034","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/apjon.apjon_22_17","article-title":"Chemotherapy and Glycemic Control in Patients with Type 2 Diabetes and Cancer: A Comparative Case Analysis","volume":"4","author":"DS Hershey","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"4","key":"pone.0354959.ref035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.6004\/jnccn.2015.0057","article-title":"Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes","volume":"13","author":"P de la Morena Barrio","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"pone.0354959.ref036","article-title":"Association of Diabetic Retinopathy and Arterial Stiffness With Cardiovascular Disease in Type 2 Diabetes","volume":"17","author":"C Agapitou","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"pone.0354959.ref037","doi-asserted-by":"crossref","first-page":"100945","DOI":"10.1016\/j.xops.2025.100945","article-title":"Nationwide Analysis of Progressive Kidney Function Decline and Diabetic Macular Edema in Type 2 Diabetes","volume":"6","author":"J Muayad","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"5","key":"pone.0354959.ref038","first-page":"1024","article-title":"Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension","volume":"106","author":"SE Moroi","year":"1999","journal-title":"Ophthalmology"},{"key":"pone.0354959.ref039","first-page":"141","article-title":"Acute macular edema following intracorporeal prostaglandin injection for erectile dysfunction","volume":"8","author":"MG Asahi","year":"2015","journal-title":"Int Med Case Rep J"},{"issue":"8","key":"pone.0354959.ref040","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/bjophthalmol-2019-315280","article-title":"Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma","volume":"104","author":"J Hu","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"pone.0354959.ref041","doi-asserted-by":"crossref","first-page":"13989","DOI":"10.1038\/s41598-023-41095-4","article-title":"Drug-drug interaction signals between loop diuretics and teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports","volume":"13","author":"T Hirai","year":"2023","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:40:59Z","timestamp":1785346859000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354959"}},"subtitle":[],"editor":[{"given":"Junzheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354959","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}